A clinical trial to learn about the effects of JFI447 and how it shows up in scans compared to FFG233 in people with solid tumors
This is an early stage clinical trial looking into a new medication called JFI447. This study, often called a 'Phase I' trial, is among the first times this drug is given to people. The main goal is to understand how JFI447 behaves in the body and how it might affect different advanced cancers. Researchers are particularly interested in seeing how it appears on medical scans. The study is also comparing JFI447 with another medication, FFG233, to learn more about both. It’s for adults who have specific types of advanced cancers, such as certain pancreatic, lung, breast, bowel, or soft tissue cancers that have spread.
At a glance
What is this study about?
This study is an early research step, sometimes called 'Phase I'. This means it’s one of the first times a new medicine, JFI447, is being tested in people. The main aim is to carefully look at how this new drug works and how your body reacts to it. Researchers are trying to understand things like how much of the drug gets into your system, how long it stays there, and whether it has any effects on your cancer.
Another important part of this research is to see how JFI447 shows up on medical scans. Scans are tools doctors use to look inside your body. By understanding how the drug appears on these scans, researchers hope to learn more about how it might be affecting the cancer. The study is also comparing JFI447 with another drug, FFG233, to gather more information about both medications.
This kind of early research is crucial for developing new treatments. It helps scientists understand if a new drug is safe enough and shows any promise before it moves on to bigger studies. The information gathered from this trial will help guide future research into JFI447 and potentially lead to new options for people living with these types of cancer.
Key takeaways
- This is an early study of a new drug, JFI447, for certain advanced cancers.
- It also compares JFI447 with another drug, FFG233.
- The study aims to understand how these drugs work and appear on scans.
- It's for adults with specific advanced pancreatic, lung, breast, bowel, or soft tissue cancers.
- Participation involves regular visits, tests, and closely watching your health.
- You can stop participating at any time.
Who may be eligible?
This study is looking for adults aged 18 or older. It is open to both men and women.
To be considered for this study, you must have been diagnosed with certain types of advanced cancer that have spread to other parts of your body. These include specific kinds of pancreatic cancer (PDAC), lung cancer (NSCLC), breast cancer (HR+/HER2- ductal and lobular BC, or TNBC), bowel cancer (CRC), or soft tissue sarcoma (STS).
The researchers will also check other health factors to make sure that taking part in the study would be safe for you. Your doctor will be able to tell you if your specific cancer type and overall health condition would make you a good fit for this research.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have advanced pancreatic, lung, breast, bowel, or soft tissue cancer that has spread?
- Are you open to having regular medical checks, including scans and blood tests?
- Are you able to attend appointments at the study site?
What does participation involve?
If you decide to take part in this study, you will likely have regular appointments at the hospital or clinic. These visits might involve physical examinations, blood tests, and medical scans (like CT or MRI scans) to see how the treatment is working and how your body is responding. You would receive the study medication, JFI447 or FFG233, as directed by the study doctors.
The research team will closely monitor your health throughout the study. There will also be a follow-up period after your treatment finishes to ensure your well-being and to collect any further important information. The total length of your participation would depend on the study design and your individual response, but this will be fully explained to you before you agree to join.
Potential risks and benefits
Locations (1)
- —UnverifiedDenmark
Common questions
What does 'Phase I' mean?
Phase I means this is one of the first times this new drug, JFI447, is being given to people. The main goal is to check its safety and how it works in the body.
What type of cancers are included?
This study is open to adults with certain advanced cancers, including specific types of pancreatic, lung, breast, bowel, and soft tissue cancers that have spread.
Will I get the new drug, JFI447, or another one?
The study is comparing JFI447 with another medication called FFG233. The research team will explain which medication you might receive.
Why are scans important in this study?
Scans help researchers see how the new drug shows up in the body and if it's having any effect on the cancer. This helps them understand how the medication works.
Can I leave the study if I change my mind?
Yes, you can choose to leave the study at any time, for any reason. Your decision will not affect your regular medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.